The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Abbey Joseph Cohen, a prominent analyst at New York headquartered Goldman Sachs says first past the post shouldn’t mean the race ends.
She argued multiple vaccines would be needed to help the world get out of this pandemic.
“The physicians and scientists with whom I have the opportunity to speak do believe that there are probably seven or eight or more that look promising right now,” Cohen said.
“They think it’s going to take multiple vaccines in order to have enough to actually make dosages available to enough people.”
https://stockhead.com.au/news/goldman-sachs-weighs-in-on-the-vaccine-debate-says-multiple-winners-needed/?utm_medium=email&utm_campaign=Lunchtime%20ASX%20Small%20Cap%20Wrap%20Friday%20May%2015&utm_content=Lunchtime%20ASX%20Small%20Cap%20Wrap%20Friday%20May%2015+CID_6b43d1a1389f2a729967ee34972a79cb&utm_source=Campaign%20Monitor&utm_term=Goldman%20Sachs%20weighs%20in%20on%20the%20vaccine%20debate%20says%20multiple%20winners%20needed
Abbey Joseph Cohen, a prominent analyst at New York headquartered Goldman Sachs says first past the post shouldn’t mean the race ends.
She argued multiple vaccines would be needed to help the world get out of this pandemic.
“The physicians and scientists with whom I have the opportunity to speak do believe that there are probably seven or eight or more that look promising right now,” Cohen said.
“They think it’s going to take multiple vaccines in order to have enough to actually make dosages available to enough people.”
https://stockhead.com.au/news/goldman-sachs-weighs-in-on-the-vaccine-debate-says-multiple-winners-needed/?utm_medium=email&utm_campaign=Lunchtime%20ASX%20Small%20Cap%20Wrap%20Friday%20May%2015&utm_content=Lunchtime%20ASX%20Small%20Cap%20Wrap%20Friday%20May%2015+CID_6b43d1a1389f2a729967ee34972a79cb&utm_source=Campaign%20Monitor&utm_term=Goldman%20Sachs%20weighs%20in%20on%20the%20vaccine%20debate%20says%20multiple%20winners%20needed
Abbey Joseph Cohen, a prominent analyst at New York headquartered Goldman Sachs says first past the post shouldn’t mean the race ends.
She argued multiple vaccines would be needed to help the world get out of this pandemic.
“The physicians and scientists with whom I have the opportunity to speak do believe that there are probably seven or eight or more that look promising right now,” Cohen said.
“They think it’s going to take multiple vaccines in order to have enough to actually make dosages available to enough people.”
https://stockhead.com.au/news/goldman-sachs-weighs-in-on-the-vaccine-debate-says-multiple-winners-needed/?utm_medium=email&utm_campaign=Lunchtime%20ASX%20Small%20Cap%20Wrap%20Friday%20May%2015&utm_content=Lunchtime%20ASX%20Small%20Cap%20Wrap%20Friday%20May%2015+CID_6b43d1a1389f2a729967ee34972a79cb&utm_source=Campaign%20Monitor&utm_term=Goldman%20Sachs%20weighs%20in%20on%20the%20vaccine%20debate%20says%20multiple%20winners%20needed
Abbey Joseph Cohen, a prominent analyst at New York headquartered Goldman Sachs says first past the post shouldn’t mean the race ends.
She argued multiple vaccines would be needed to help the world get out of this pandemic.
“The physicians and scientists with whom I have the opportunity to speak do believe that there are probably seven or eight or more that look promising right now,” Cohen said.
“They think it’s going to take multiple vaccines in order to have enough to actually make dosages available to enough people.”
https://stockhead.com.au/news/goldman-sachs-weighs-in-on-the-vaccine-debate-says-multiple-winners-needed/?utm_medium=email&utm_campaign=Lunchtime%20ASX%20Small%20Cap%20Wrap%20Friday%20May%2015&utm_content=Lunchtime%20ASX%20Small%20Cap%20Wrap%20Friday%20May%2015+CID_6b43d1a1389f2a729967ee34972a79cb&utm_source=Campaign%20Monitor&utm_term=Goldman%20Sachs%20weighs%20in%20on%20the%20vaccine%20debate%20says%20multiple%20winners%20needed
Hannam & Partners has set a price target for Greatland Gold PLC of 12.9p, implying 47% upside from the current share price.
The share price valuation derives in part from a calculation of the net present value of Greatland’s Havieron gold project in the Paterson region of Western Australia.
Hannam sets the value of Havieron at a preliminary US$1.67bn, and estimates that Greatland’s share of the development costs is likely to amount to US$33.9mln.
“The significance of Havieron became apparent in November 2018, when an intercept of 275 metres at 4.8 grams per tonne gold and 0.6% copper was released to the market,” writes Hannam’s analyst Andrei Kroupnik.
https://www.proactiveinvestors.co.uk/companies/news/919587/greatland-gold-valued-at-129p-by-hannam--partners-based-on-a-us167bn-valuation-for-havieron-919587.html
Upcoming bank holidays in England and Wales, 2020:
8 May Friday Early May bank holiday (VE day)
25 May Monday Spring bank holiday
31 August Monday Summer bank holiday
25 December Friday Christmas Day
28 December Monday Boxing Day (substitute day)
This is all I could find:
We have watched this company for a while, but it seems that no-one else has been. And we know that there are all sorts of reasons why investors and traders might want to ignore this stock. However we see two catalysts that could see the shares absolutely skyrocket within six months. Yes: this really could be a ten bagger or more by October, probably well before!
One is a potential sale of a non-core asset that could easily bring in cash equivalent of a large part or all of the current market cap.
And the other catalyst is the major part of the business starting to generate cash. Lots of it. In fact it could be generating up to a third of the current market cap PER MONTH!
And that is why the shares are set to roof it!
From Monday Novacyt will supply 288,000 diagnostic tests per week for use in the NHS for an initial six months. There is an option to extend the agreement.
The company is already supplying more than 20 hospitals with its tests after earlier orders from Public Health England.
Novacyt’s Primerdesign subsidiary is developing the test in Southampton. This month the test became the second to be listed by the World Health Organisation as eligible for emergency use, after one produced by Roche, the Swiss multinational.
It expects to double production over the next three months to about eight million tests a month.
https://www.thetimes.co.uk/edition/business/novacyt-boosts-covid-19-testing-in-nhs-deal-3w7bzr5m9
More and more independent researchers are considering that the virus causing COVID-19 may ultimately become seasonal. Dr. William Schaffner, an expert in infectious diseases, revealed the following in a statement to Healthline, “We think this coronavirus will likely become more prominent during winter in the Southern Hemisphere… and cycle back to the Northern Hemisphere in the next winter season. We’ll be dealing then with influenza, other respiratory viruses, and the coronavirus.”
The question is: Is this even possible? Could a new virus just show up and become a new seasonal burden we have to fight? The answer is, tragically, ‘yes’, and historians believe this has happened before with a more familiar virus - influenza. The first recordings of the flu date back to 1580.
https://www.ba-bamail.com/content.aspx?emailid=35521
More and more independent researchers are considering that the virus causing COVID-19 may ultimately become seasonal. Dr. William Schaffner, an expert in infectious diseases, revealed the following in a statement to Healthline, “We think this coronavirus will likely become more prominent during winter in the Southern Hemisphere… and cycle back to the Northern Hemisphere in the next winter season. We’ll be dealing then with influenza, other respiratory viruses, and the coronavirus.”
The question is: Is this even possible? Could a new virus just show up and become a new seasonal burden we have to fight? The answer is, tragically, ‘yes’, and historians believe this has happened before with a more familiar virus - influenza. The first recordings of the flu date back to 1580.
https://www.ba-bamail.com/content.aspx?emailid=35521
Thanks to Moneymunch, KnightRider1, TC101, scott1690, dusterhater and Stocksbofs2 for all the information; much appreciated.
This is what I was referring to:
New York/London, 13 January 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that it has appointed advisers in relation to an intended redomicile of the Company to Bermuda which is anticipated to occur by Q2-2020, as a consequence of the redomicile the Company will not be seeking to re-admit its ordinary shares on AIM and will therefore seek shareholder consent for its shares to be cancelled from AIM when the redomicile occurs.
A further announcement will be made in due course.
Furthermore, the Company intends to cancel its ADR program and have its Bermuda common shares listed on Nasdaq.
I've searched for the "further announcement", but can't find one .
Hopefully they've changed their mind.
I've heard that Tiziana plans to delist from AIM, but stay listed on Nasdaq; is this true?
The UK government has promised to ramp up testing of suspected coronavirus cases, although the measures still fall significantly short of the levels called for by the World Health Organization (WHO).
England’s chief medical officer, Prof Chris Whitty, defended the government’s approach to testing but said it intended to scale it up, noting that efforts were already “substantial” and that more than 44,000 tests had been conducted.
The move comes after the head of the WHO launched a strongly worded attack on governments that had neglected or held back testing, warning that they could not fight the pandemic blindfolded.
Dr Tedros Adhanom Ghebreyesus said: “We have not seen an urgent enough escalation in testing, isolation and contact tracing, which is the backbone of the response. And to do that, you must test and isolate. You cannot fight the fire blindfolded. And we cannot stop this pandemic, if we don’t know who is infected.
“We have a simple message for all countries Test, test, test. Test every suspected case.” He said the most effective way to prevent infections and save lives was “breaking the chains of transmission”.
https://www.theguardian.com/world/2020/mar/16/coronavirus-government-vows-accelerate-testing
Newcrest Reports Further Outstanding Drill Results at Havieron
Stage 2 of Farm-in expected to be completed by end of March 2020
Greatland Gold plc (AIM:GGP), the precious and base metals exploration and development company, is pleased to provide an update on Newcrest's drilling campaign at Greatland's 100% owned Havieron deposit in the Paterson region of Western Australia.
Greatland notes the release of an ASX announcement titled "Exploration and Guidance Update" by Newcrest Mining Ltd ("Newcrest") earlier today.
https://hotcopper.com.au/threads/ann-exploration-guidance-update-11-march-2020.5276089/
Saturday February 29 2020, 12.01am, The Times:
A British-listed biotechnology company has signed a distribution agreement in Asia for its coronavirus test and a manufacturing agreement with an American healthcare group.
Novacyt, which specialises in clinical diagnostics, has reported a sharp rise in demand for its test since the outbreak of the deadly disease from China.
It has signed its first big agreement for the covid-19 test with an unnamed life sciences company to supply the test to two Asian countries outside China. Separately, Novacyt said that it had an agreement with an unnamed US group for the manufacture and sale of its tests.
Novacyt is also listed in Paris and is headquartered in France, but most of its operations are in Camberley, Surrey.
Primerdesign, its Southampton-based subsidiary, is developing the test, which is under review by the US Food and Drug Administration for emergency approval, which would allow it to be used for clinical diagnoses.
Other national health authorities are regulating tests in different ways. Novacyt said that some had approved locally made tests for emergency use and some were also reviewing Primerdesign’s test.
Public Health England has invited manufacturers to submit tests for urgent evaluation. Novacyt said that it “is not known at this time what conclusions or guidance PHE will subsequently give to the NHS for covid-19 testing”. It said that it had put in place measures to boost production, including using capacity at both its UK sites.
Graham Mullis, 57, Novacyt’s chief executive said: “We believe the Primerdesign test remains among the quickest and most accurate tests available for covid-19, as well as being stable for long-distance shipping without the need for specialist cold-chain shipping.”
Its shares closed up by 32½p, or 28.3 per cent, at 147½p last night.